Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

References

• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). [Internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic myelogeneous leukemia. Version 2.2014. United States. 2013. Available from: www.nccn.org/professionals/physician_gls/pdf/cml.pdf.1-91
   Google Scholar
• Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:409–429.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium—the just price. J Clin Oncol 2013;31:3600–3604.
   PubMed Web of Science ®Google Scholar
• Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013;119:3900–3902.
   PubMed Web of Science ®Google Scholar
• Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933–980.
   PubMed Web of Science ®Google Scholar
• Ludwig Boltzmann Institut. [Internet]. LBI Horizon Scanning Projekt. Vienna; 2008. Available from: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie
   Google Scholar
• Gesundheit Österreich GmbH, BIQG, HTA-Arbeitsgruppe. Nationale HTA-Strategie. Version 1.0. Im Auftrag des Bundesministeriums für Gesundheit. 2009;1:4–5.
   Google Scholar
• Fröschl B, Bornschein B, Brunner-Ziegler S, et al. Methodenhandbuch für Health Technology Assessment Version 1.2012. Im Auftrag des Bundesministeriums für Gesundheit. 2012;1.
   Google Scholar
• Rochau U, Sroczynski G, Wolf D, et al. Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leuk Lymphoma 2014;55:1758–1767.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
   Google Scholar
• Weinstein MC. Decision rules for incremental cost-effectiveness analysis. In: Jones AM, editor. The Elgar companion to health economics. Cheltenham, UK: Edward Elgar Publishing Ltd; 2006. pp 469–478.
   Google Scholar
• Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14:259–265.
   PubMed Web of Science ®Google Scholar
• Phillips C. What is cost effectiveness? In: Health Economics. 2nd ed. 2009. Available from: www.whatisseries.co.uk.
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press; 2005.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—1. Value Health 2012;15:796–803.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—3. Value Health 2012;15:812–820.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013;16:e1–e5.
   PubMed Web of Science ®Google Scholar
• OeGHO. [Internet]. The Austrian CML-Registry. 2014. Available from: www.cml-registry.com/login_en.xhtml
   Google Scholar
• Schmidt S, Wolf D, Thaler J, et al. First annual report of the Austrian CML registry. Wien Klin Wochenschr 2010;122:558–566.
   PubMed Web of Science ®Google Scholar
• Statistik Austria. [Internet]. Sterbetafeln. 2012. Available from: http://www.statistik.at/web_de/statistiken/bevoelkerung/sterbetafeln/index.html
   Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–3546.
   PubMed Web of Science ®Google Scholar
• Pavey T, Hoyle M, Ciani O, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 2012;16:iii–iv, 1–277.
   Web of Science ®Google Scholar
• Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl. 7):vii72–vii77.
   PubMed Web of Science ®Google Scholar
• AGfSZT. ASCTR (Austrian Stem Cell Transplantation Registry)2011. Presented at: EBMT Meeting, April 2012, Geneva.
   Google Scholar
• Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002;100:3877–3886.
   PubMed Web of Science ®Google Scholar
• Auberger J, Clausen J, Kircher B, et al. Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients. Eur J Haematol 2011;87: 531–538.
   PubMed Web of Science ®Google Scholar
• Devergie A. Graft versus host disease. In: Apperley J, Carreras E, Gluckman E, et al., editors. ESH-EBMT handbook on haemopoietic stem cell transplantation. [Internet]. 2008; pp 219–235. Available from: www.ebmt.org
   Google Scholar
• EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515–526.
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574–2583.
   PubMed Web of Science ®Google Scholar
• Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010;26:183–191.
   PubMed Web of Science ®Google Scholar
• Österreichische Apotheker-Verlagsgesellschaft m.b.H. [Internet]. Warenverzeichnis. Austria. 2012. Available from: http://warenverzeichnis.apoverlag.at/
   Google Scholar
• Bundesministerium für Gesundheit. [Internet]. Leistung sorientierte Krankenanstaltenfinanzierung (LKF). Austria. 2013. Available from: http://bmg.gv.at/home/Schwerpunkte/Krankenanstalten/LKF_Leistungsorientierte_Krankenanstaltenfinanzierung/
   Google Scholar
• Bundesministerium für Gesundheit. [Internet]. Programmpakete KDok für landesgesundheitsfondsfinanzierte Krankenanstalten. Austria. 2012. Available from: http://bmg.gv.at/home/Schwerpunkte/Gesundheitssystem_Qualitaetssicherung/Dokumentation/Programmpakete_KDok_fuer_landesgesundheitsfondsfinanzierte_Krankenanstalten
   Google Scholar
• Hauptverband der österreichischen Sozialversicherungsträger. [Internet]. Verfahrensordnung zur Herausgabe des Erstattungskodex nach § 351g ASVG – VO-EKO. Austria. 2004. Available from: http://www.aphar.at/pdfs/avsv-2004-047.pdf
   Google Scholar
• Apotheke adhoc. European Medicines Agency. [Internet]. Glivec wird generisch. Berlin. 27 Feb 2013. Available from: www.apotheke-adhoc.de/nachrichten/nachricht-detail/ema-imatinib-wird-generisc/?no_cache = 1&L = 0
   Google Scholar
• Drug.com. [Internet]. Generic Sprycel availability. United States. 2014. Available from: www.drugs.com/availability/generic-sprycel.html
   Google Scholar
• Drug.com. [Internet]. Generic Tasigna availability. United States. 2014. Available from: www.drugs.com/availability/generic-tasigna.html
   Google Scholar
• Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press; 2006.
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—6. Value Health 2012;15:835–842.
   PubMed Web of Science ®Google Scholar
• Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479–500.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997;127:1080–1088.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). [Internet]. Process and methods guides. Guide to the methods of technology appraisal 2013. UK. 2013. Available from: http://www.nice.org.uk/article/PMG9/1-93
   Google Scholar
• Raad voor de Volksgezondheid en Zorg aan de minister van Volksgezondheid. [Internet]. Zinnige en duurzame zorg. The Netherlands. 2006. Available from: www.rvz.net/uploads/docs/Advies_-_Zinnige_en_duurzame_zorg.pdf.1-112
   Google Scholar
• Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib—a Swedish model application. Acta Oncol 2010;49:851–858.
   PubMed Web of Science ®Google Scholar
• Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health 2011;14:1057–1067.
   PubMed Web of Science ®Google Scholar
• Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626–633.
   PubMed Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439–4442.
   PubMed Web of Science ®Google Scholar
• Wise J. NICE backs leukaemia drug after manufacturer drops price. BMJ 2012;344:e2274.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533–539.
   PubMed Web of Science ®Google Scholar
• Center for the Evaluation of Value and Risk in Health. [Internet]. The Cost-Effectiveness Analysis Registry. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. United States. 2014. Available from: www.cearegistry.org
   Google Scholar
• Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:225–234.
   PubMed Web of Science ®Google Scholar
• Woods B, Hawkins N, Dunlop W, et al. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 2012;15:759–770.
   PubMed Web of Science ®Google Scholar
• Lu L, Peters J, Roome C, et al. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. Int J Technol Assess Health Care 2012;28:241–248.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122: 515–522.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Bhalla K, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112(Suppl. 1): Abstract 3238.
   Google Scholar
• Kantarjian H, O’Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109: 1556–1560.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Lopez-Guillermo A, Bosch F, et al. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996;57:286–291.
   PubMed Web of Science ®Google Scholar
• Niederösterreichischer Gesundheits- und Sozialfonds (NÖGUS). Ambulanzkatalog.2012.
   Google Scholar
• Tiroler Gesundheitsfonds (TGF). Ambulanzabrechnungskatalog.2012.
   Google Scholar
• Burgenländische Gebietskrankenkasse (BGKK). Zusatzvere inbarung 2010/2011/2012. 2012.
   Google Scholar
• Kärntner Gebietskrankenkasse (KGKK).Honorartarif. 2012.
   Google Scholar
• Niederösterreichische Gebietskrankenkasse (NÖGKK).Honora rordnung. 2011.
   Google Scholar
• Oberösterreichische Gebietskrankenkasse (OÖGKK). Arbeits behelf Honorarordnung für Ärzte für Allgemeinmedizin und Fachärzte.2010.
   Google Scholar
• Salzburger Gebietskrankenkasse (SGKK). Honorartarif zum Gesamtvertrag.2012.
   Google Scholar
• Steirische Gebiertskrankenkasse (StGKK). Honorarverordnung für Einzelverträge und Fachärzte.2011.
   Google Scholar
• Tiroler Gebietskrankenkasse (TGKK). Honorarordnung für Ärzte und Allgemeinmedizin und Fachärzte.2010.
   Google Scholar
• Vorarlberger Gebietskrankenkasse (VGKK). Honorartariffür Vorarlberg, gültig ab 01.01.2012. 2012.
   Google Scholar
• Wiener Gebietskrankenkasse (WGKK). Tarif für allgemeine Vertragsfachärzte. 2012.
   Google Scholar
• Kattan MW. Encyclopedia of medical decision making. Thousand Oaks, CA: SAGE Publications; 2009.
   Google Scholar
• Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs. Cambridge: Cambridge University Press; 1993.
   Google Scholar
• Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459–467.
   PubMed Web of Science ®Google Scholar